Novo Nordisk (NYSE: NVO) closed the most recent trading session at $44.01, recording a decline of 1.23%, a steeper drop than the S&P 500’s daily loss of 0.59%.
The Dow Jones Industrial Average also fell 0.6% during the same session, while the tech-heavy Nasdaq slipped 0.65%, both outperforming NVO on the day.
Over the prior month, Novo Nordisk shares shed 3.94%, underperforming the Medical sector’s loss of 0.36% and the S&P 500’s broader decline of 1.37%.
Investors and analysts are closely watching the company’s upcoming earnings disclosure, with consensus estimates projecting an EPS of $0.80, representing a 21.57% drop compared to the same quarter of the prior year.
Revenue expectations for the quarter point to $11.47 billion, which would mark a 2.35% decrease year-over-year, adding further pressure to an already cautious outlook surrounding the Danish drugmaker.
For the full fiscal year, the Zacks Consensus Estimates project earnings of $3.45 per share and total revenue of $45.79 billion, reflecting changes of -12.88% and -2.11%, respectively, from the prior year.
Despite the bearish headline figures, the Zacks Consensus EPS estimate has moved 1.86% higher over the past month, suggesting some analysts are modestly warming to near-term prospects for the company.
Novo Nordisk currently holds a Zacks Rank of #3 (Hold), placing it in the middle of a system that spans from #1 (Strong Buy) to #5 (Strong Sell), with #1 ranked stocks averaging an annual return of +25% since 1988.
On the valuation front, NVO trades at a Forward P/E ratio of 12.91, a notable discount to the industry average Forward P/E of 15.55, suggesting the stock may be attractively priced relative to its Large Cap Pharmaceuticals peers.
The company’s PEG ratio currently stands at 1.5, below the Large Cap Pharmaceuticals industry average of 2.01, indicating that Novo Nordisk’s growth-adjusted valuation remains relatively favorable compared to sector counterparts.
The Large Cap Pharmaceuticals industry, which sits within the broader Medical sector, holds a Zacks Industry Rank of 101, placing it in the top 42% of more than 250 tracked industry groups.
Research from Zacks shows that the top 50% of ranked industries tend to outperform the bottom half by a factor of 2 to 1, giving NVO’s sector positioning some longer-term significance for investors monitoring the stock.
